InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,650.00
(
0.05%
)
Dow Jones
39,512.84
(
0.32%
)
Brent Oil
82.59
(
0.00%
)
Bitcoin
61,620.45
(
1.35%
)
Post# of 1721
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

BottomBounce

Send PM Follow Ignore
Followers 898
Posts 148975
Boards Moderated 0
Alias Born 08/13/2010

BottomBounce

Re: None

Wednesday, 07/04/2018 1:39:49 PM

Wednesday, July 04, 2018 1:39:49 PM

Post# of 1721
$INSY Insys' Awaits FDA Verdict For Pain Drug

Company: Insys Therapeutics Inc
INSY 1.26%
.
Type of Application: NDA.
Candidate: Buprenorphine sublingual spray.
Indication: moderate-to-severe acute pain.
Date: July 28.

The NDA was accepted for review based on a pivotal trial that met its primary efficacy endpoint.

Nothing I say, post, or do should ever be considered financial advice. I may be holding a long, short or no position. I am NOT or NEVER have I been compensated to post on here or anywhere and all my posts are for entertainment purposes only.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up